Select Clinical Trial
Protocol Number: SWOG 1714
Protocol Title: A prospective observational study to develop a predictive model of taxane-induced peripheral neuropathy (nerve damage) in patients with non-small cell lung, primary breast, or primary ovarian cancer.
Eligibility: Men and women age 18 and older with non-small cell lung, primary breast, or primary ovarian cancer that are planning to start treatment with a taxane-based chemotherapy. Patients with pre-existing neuropathy are eligible, including those with diabetes and neurological conditions such as multiple sclerosis or Parkinson’s disease.
Contact Information: (910) 715-2200